Navigation Links
Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma
Date:12/7/2009

lymphopenia (77%).

At active dose levels tested in this phase 1 clinical trial, permanent treatment discontinuation due to adverse events resulted mainly from fully reversible and transient neurological events during the first few days of treatment. A low ratio of B to T cells in peripheral blood was identified as a predictive biomarker for neurological events in patients with NHL. Based on these findings, and the possibility of adaptation of T cells by gradually increasing doses of blinatumomab, Micromet has developed a biomarker-guided dosing schedule designed to decrease the early neurological events and to provide all patients with the opportunity to reach the dose of 60 micrograms/squaremeter per day.

"We are very excited about the high response rate seen in patients with NHL treated at the 60-microgram dose level and are now planning larger studies to confirm these encouraging results," commented Dr. Jan Fagerberg, Micromet's Chief Medical Officer. "We expect that the biomarker-guided dosing schedule will accelerate the clinical development of blinatumomab in all relevant B-cell lymphoma indications."

(1) Nagorsen, D. et al. (2009) Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin's Lymphoma Patients Treated with 60 Microgram/Squaremeter per Day of BiTE Antibody Blinatumomab. ASH Annual Meeting, abstract no. 2723.

About BiTE Antibodies

BiTE® antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially el
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
2. Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability
3. New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology
4. Circassia Announces Successful Results From Phase II Clinical Study of ToleroMune(R) Cat Allergy Therapy
5. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
6. Randy Olver Named Emdat CEO, Will Lead Next Phase of Growth for Medical Transcription Solutions Provider
7. NovaRx Corporation Announces FDA Approval of Protocol Amendment to Special Protocol Assessment (SPA) for Phase III Lucanix(R) Study in Non-Small Cell Lung Cancer (NSCLC)
8. AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer
9. Carmel Pharma Introduces PhaSeal Secondary Set (C60)
10. Carmel Pharma Introduces PhaSeal Secondary Set (C60)
11. AcelRx Announces Successful Completion of End-of-Phase 2 Meeting on ARX-01, Sufentanil NanoTab PCA System for Post-Operative Pain Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... ... 02, 2015 , ... Back packs can be dangerous? Whaaat?! , Not the ... wreck havoc on a kid's spine. With school starting again, most kids will be ... sure you are aware of how to help them prevent injuries by understanding backpack ...
(Date:8/1/2015)... ... August 01, 2015 , ... The condition where veins ... men and women often causing pain and discomfort. Those who spend a lot of ... and Northeast Houston Vein Center is doing what it can to create awareness and ...
(Date:8/1/2015)... ... August 01, 2015 , ... Brig and Lita Hart, icons of the ... of their Healthy Home mission with the HOPE Movement of EvolvHealth. In what has ... both companies have agreed to join their missions of purpose together to change the ...
(Date:8/1/2015)... ... ... Lume Wellness creators Alex, Robert, and Sam have announced update 3.0.1 to ... , The app is designed to track various metrics of wellness, including physical activity, ... health and use this information for positive behavior modification. Lume Wellness keeps track of ...
(Date:8/1/2015)... ... ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for Addiction ... stepping off Springer Mountain and heading north. Since that day, Phil has hiked over 1400 ... greeted by friends and family. He visited CCAR and left an inspirational message to ...
Breaking Medicine News(10 mins):Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2
... ... ... ... ...
... ... ... , ... ...
... ... ... ... ...
... shown to be effective in breast cancer packs an effective ... a specific genetic mutation, a study at UCLA,s Jonsson Comprehensive ... when given together proved to significantly inhibit tumor growth in ... mutation that results in an aggressive form of the disease, ...
... scientists studying acute forms of Leukaemia have identified a new ... the growth of diseased cells. The research, reported in ... to genes, which if targeted could prevent diseased cells from ... the University of Vienna, carried out their research on acute ...
... bone mineral density, strength and postural balance due to ... group of women but also for elderly men, says ... and continues "It is well known that the risk ... result of weaker bones, poorer balance and attenuated ability ...
Cached Medicine News:Health News:AUA Responds to American Cancer Society Guideline for the Early Detection of Prostate Cancer 2Health News:AUA Responds to American Cancer Society Guideline for the Early Detection of Prostate Cancer 3Health News:AUA Responds to American Cancer Society Guideline for the Early Detection of Prostate Cancer 4Health News:AUA Responds to American Cancer Society Guideline for the Early Detection of Prostate Cancer 5Health News:AUA Responds to American Cancer Society Guideline for the Early Detection of Prostate Cancer 6Health News:Testimony Before the House Committee on Foreign Affairs Regarding the Fiscal Year 2011 Budget Request 2Health News:Testimony Before the House Committee on Foreign Affairs Regarding the Fiscal Year 2011 Budget Request 3Health News:Testimony Before the House Committee on Foreign Affairs Regarding the Fiscal Year 2011 Budget Request 4Health News:Testimony Before the House Committee on Foreign Affairs Regarding the Fiscal Year 2011 Budget Request 5Health News:Testimony Before the House Committee on Foreign Affairs Regarding the Fiscal Year 2011 Budget Request 6Health News:Testimony Before the House Committee on Foreign Affairs Regarding the Fiscal Year 2011 Budget Request 7Health News:Testimony Before the House Committee on Foreign Affairs Regarding the Fiscal Year 2011 Budget Request 8Health News:Testimony Before the House Committee on Foreign Affairs Regarding the Fiscal Year 2011 Budget Request 9Health News:Testimony Before the House Committee on Foreign Affairs Regarding the Fiscal Year 2011 Budget Request 10Health News:Testimony Before the House Committee on Foreign Affairs Regarding the Fiscal Year 2011 Budget Request 11Health News:Testimony Before the House Committee on Foreign Affairs Regarding the Fiscal Year 2011 Budget Request 12Health News:Testimony Before the House Committee on Foreign Affairs Regarding the Fiscal Year 2011 Budget Request 13Health News:Testimony Before the House Committee on Foreign Affairs Regarding the Fiscal Year 2011 Budget Request 14Health News:Testimony Before the House Committee on Foreign Affairs Regarding the Fiscal Year 2011 Budget Request 15Health News:Testimony Before the House Committee on Foreign Affairs Regarding the Fiscal Year 2011 Budget Request 16Health News:Testimony Before the House Committee on Foreign Affairs Regarding the Fiscal Year 2011 Budget Request 17Health News:Marketech Celebrates 25 Years of Service 2Health News:Marketech Celebrates 25 Years of Service 3Health News:Marketech Celebrates 25 Years of Service 4Health News:Marketech Celebrates 25 Years of Service 5Health News:Herceptin and Tykerb effective against a subset of gastric cancers 2Health News:Herceptin and Tykerb effective against a subset of gastric cancers 3Health News:Targeting leukemia cell's gene 'addiction' presents new strategy for treatment 2Health News:Soccer reduces risk of falls and bone fractures 2Health News:Soccer reduces risk of falls and bone fractures 3
(Date:7/31/2015)... 31, 2015 Magnaquest, a ... data and cloud computing operators has signed a ... giant for Internet of Things (IoT) related initiative. ... on subscription model.      (Logo: ... striving for business innovations to make healthcare services ...
(Date:7/30/2015)... Inc. (NYSE: RMD ) today announced results for ... quarter was $453.1 million, a 9 percent increase compared ... percent increase on a constant currency basis).  Net income ... 30, 2014.  Diluted earnings per share for the quarter ... 2014.  The results for the quarter ...
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex ... it will report its second quarter 2015 financial results ... a conference call and live webcast at 4:30 p.m. ... clinical development programs and a general corporate update. ... the Investor Relations page of the OncoGenex website at ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... Corporation,(Nasdaq: IOMI ) today announced that interim results ... patch-based vaccine for travelers, diarrhea,found that all subjects who ... -- mounted an immune response, demonstrating that even elderly,subjects ... The trial was designed to compare the number of ...
... N.C., Aug. 10 More than 33% ... identify clinical,investigators 50% faster than their industry ... clinical trial costs while improving quality,by employing ... to research probing clinical trial excellence by,pharmaceutical ...
Cached Medicine Technology:Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers' Diarrhea Patch Vaccine 2Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers' Diarrhea Patch Vaccine 3Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers' Diarrhea Patch Vaccine 4Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management 2
Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)...
Malaria device / strip (3 line, P.f/P.v Ag Test-pLDH)...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
Medicine Products: